Abstract
Background/Aim: Regimens with bevacizumab (Bev) have high response rates. We previously showed the efficacy of Bev plus carboplatin (CBDCA)/nab-paclit......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
